Nflection Therapeutics

Boston, United States · Founded 2014 · $20.0M raised

Employees
1–10
Founded
2014
Business Model
B2B
Total Funding
$20.0M
Last Round
$20.0M Series AMay 2024
Rounds
1

About

NFlection Therapeutics is a clinical-stage biopharmaceutical company focused on developing first-in-class topical MEK (mitogen-activated protein kinase kinase) inhibitors for rare skin disorders driven by aberrant activation of the RAS-MAPK pathway. The company's lead programs target neurofibromatosis type 1 (NF1) cutaneous neurofibromas, immunosuppressant-mediated squamous cell carcinoma, and congenital birthmarks including keratinocytic epidermal nevi and nevi sebacei. NFlection completed a Phase 2b clinical trial of its lead compound NFX-179 topical gel in the treatment of cutaneous neurofibromas, with positive results announced in 2023, and is headquartered in Boston, Massachusetts.

Summary

Nflection Therapeutics is a Biotech company based in Boston, United States, founded in 2014. It has raised $20.0M in total across 1 round, most recently a $20.0M Series A round in May 2024. Investors include venBIO Partners and F-Prime Capital.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries AMay 2024
$20.0M

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Nflection Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/nflection-therapeutics"><img src="https://indexed.vc/api/badge/company/nflection-therapeutics" alt="Nflection Therapeutics on Indexed.vc" width="260" height="76" /></a>